Clinical Trial

Relation of IL23R and IL17A Gene Polymorphisms Plus Serum Levels of IL23 and IL17A to Rheumatoid Arthritis Susceptibility and Activity

Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated October 6, 2022 (before its estimated August 4, 2025 completion). Its status may not reflect the trial's current state.
Summary
Assess the impact of rs2201841 and rs2275913 single nucleotide polymorphism of host genes IL-23R and IL-17A respectively on susceptibility of rheumatoid arthritis . Determine serum levels of IL-23 and IL-17A using ELISA test to investigate their correlation to rheumatoid arthritis disease activity . Compare the 4 biomarkers IL-23R and IL-17A genetic polymorphism and levels of IL-23 and IL-17A as predictors of rheumatoid arthritis susceptibility and disease activity .
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT05570513
Lead Sponsor Assiut University
Conditions Rheumatoid Arthritis
Enrollment 90 participants
Start Date 2023-08-04
Primary Completion 2025-08-04 (estimated)
Study Completion 2026-08-04 (estimated)
Updated on ClinicalTrials.gov 2022-10-06